The Potential and Challenges of the Cancer Vaccine for the Prevention and Treatment of Cancers

Vaccines elicit immune defenses against a particular pathogen by delivering antigens, molecules, or molecular fragments that trigger an immune response. Cancer vaccines represent a transformative and promising frontier in oncology, aiming not only to prevent malignancies but also to treat established tumors by harnessing the immune system. Prophylactic vaccines, such as those targeting cancer-related viral antigens, have successfully reduced the incidence of virus-induced cancers. Therapeutic cancer vaccines—particularly those targeting tumor-specific neoantigens—have shown promise but face substantial biological and translational challenges. This review summarizes current progress in both prophylactic and therapeutic cancer vaccines, focusing on antigen targets, delivery platforms, and clinical development. We discuss major barriers, including tumor heterogeneity, immune tolerance, and immunosuppressive tumor microenvironments, as well as translational challenges such as manufacturing complexity, cost, and scalability. Finally, we highlight emerging strategies—including mRNA platforms, artificial intelligence (AI)-guided antigen selection, and combination immunotherapies—aimed at overcoming these limitations and improving clinical efficacy.

Authors

Institutions

Publication Details

Journal
Vaccines
Published
2026-11-13
DOI
https://doi.org/10.3390/vaccines14110978
Primary Topic
Immunotherapy and Immune Responses
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The Potential and Challenges of the Cancer Vaccine for the Prevention and Treatment of Cancers

Yanlin Yu
3 links
Vaccines
Immunotherapy and Immune Responses
article

The Potential and Challenges of the Cancer Vaccine for the Prevention and Treatment of Cancers

Yanlin Yu
article en

Abstract

Vaccines elicit immune defenses against a particular pathogen by delivering antigens, molecules, or molecular fragments that trigger an immune response. Cancer vaccines represent a transformative and promising frontier in oncology, aiming not only to prevent malignancies but also to treat established tumors by harnessing the immune system. Prophylactic vaccines, such as those targeting cancer-related viral antigens, have successfully reduced the incidence of virus-induced cancers. Therapeutic cancer vaccines—particularly those targeting tumor-specific neoantigens—have shown promise but face substantial biological and translational challenges. This review summarizes current progress in both prophylactic and therapeutic cancer vaccines, focusing on antigen targets, delivery platforms, and clinical development. We discuss major barriers, including tumor heterogeneity, immune tolerance, and immunosuppressive tumor microenvironments, as well as translational challenges such as manufacturing complexity, cost, and scalability. Finally, we highlight emerging strategies—including mRNA platforms, artificial intelligence (AI)-guided antigen selection, and combination immunotherapies—aimed at overcoming these limitations and improving clinical efficacy.

VaccinesVol. 14(11)
National Institutes of Health (US), National Cancer Institute (US), Center for Cancer Research (US)
Good health and well-being
Immunotherapy and Immune Responses
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon